18f-αvβ6-bp
PeptideexperimentalImaging agent
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2016 (NCT03164486)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Integrin alpha-V/beta-6INHIBITOR
Integrin alpha-V/beta-6 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
- Imaging
- 18-fluorine
Oral
No
Parenteral
No
Topical
No
Also known as
- 18f-alphavbeta6-bp
- 18f-αvβ6-bp
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05452005 | Phase 1 | Sep 13, 2022 | Department of Defense, University of California, Davis |
| NCT04376593 | Early Phase 1 (Phase 1) | May 31, 2020 | University of California, Davis |
| NCT03164486 | Early Phase 1 (Phase 1) | Nov 1, 2016 | National Cancer Institute (NCI), University of California, Davis |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of California, Davis | Academic/Hospital | 3 | 3 | 1 | 2016 |
| Department of Defense | Government | 1 | 0 | 1 | 2022 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2016 |
3 organizations
Page 1 / 1